Israel Englander Neu Base Therapeutics, Inc. Transaction History

Millennium Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.41 - $1.3 $9,146 - $29,001	22,309 New	22,309 $9,000
Q2 2022 Aug 15, 2022	SELL	$0.82 - $1.93 $14,247 - $33,533	-17,375 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.26 - $2.95 $12,445 - $29,137	-9,877 Reduced 36.24%	17,375 $33,000
Q4 2021 Feb 14, 2022	SELL	$2.6 - $4.18 $2,464 - $3,962	-948 Reduced 3.36%	27,252 $77,000
Q3 2021 Nov 15, 2021	SELL	$3.27 - $4.76 $476,831 - $694,103	-145,820 Reduced 83.79%	28,200 $102,000
Q2 2021 Aug 16, 2021	BUY	$4.63 - $7.34 $591,561 - $937,809	127,767 Added 276.24%	174,020 $834,000
Q1 2021 May 17, 2021	BUY	$6.92 - $12.36 $183,767 - $328,232	26,556 Added 134.82%	46,253 $342,000
Q4 2020 Feb 16, 2021	BUY	$6.92 - $9.25 $136,303 - $182,197	19,697 New	19,697 $138,000
Q3 2020 Nov 16, 2020	SELL	$7.25 - $9.71 $3.04 Million - $4.07 Million	-419,325 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$6.69 - $11.51 $2.65 Million - $4.56 Million	395,890 Added 1689.31%	419,325 $3.68 Million
Q1 2020 May 14, 2020	SELL	$4.77 - $8.23 $24,889 - $42,944	-5,218 Reduced 18.21%	23,435 $167,000
Q4 2019 Feb 14, 2020	BUY	$4.5 - $8.1 $128,938 - $232,089	28,653 New	28,653 $206,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.